Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
114 Colorectal Cancer Trials near Baltimore, MD
Power is an online platform that helps thousands of Colorectal Cancer patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerDuloxetine for Colorectal Cancer
Baltimore, MarylandThis phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:25+
Sex:All
220 Participants Needed
Vitamin D3 + Chemotherapy + Bevacizumab for Colorectal Cancer
Baltimore, MarylandThis trial is testing if vitamin D3 along with regular cancer drugs and another drug that helps the immune system can better treat colorectal cancer that has spread. Vitamin D3 may help the body use essential minerals, making the cancer drugs more effective. Vitamin D3 has been shown to slow down cancer cell growth and help them mature, and it has been effective in reducing intestinal tumors in animal studies.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
455 Participants Needed
Amivantamab + FOLFIRI for Colorectal Cancer
Baltimore, MarylandThe purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:ILD, Second Malignancy, HER2-positive, Others
Must Not Be Taking:Irinotecan, EGFR Agents, MET Agents
700 Participants Needed
Amivantamab + Chemotherapy vs Cetuximab + Chemotherapy for Colorectal Cancer
Baltimore, MarylandThe purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type (WT) unresectable or metastatic left-sided colorectal cancer.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:ILD, Pneumonitis, Pulmonary Fibrosis, Others
Must Not Be Taking:EGFR Inhibitors, MET Inhibitors
1000 Participants Needed
MRTX849 + Cetuximab for Colorectal Cancer
Baltimore, MarylandThis trial is testing a new treatment for patients with colorectal cancer. The treatment combines two drugs that work together to block cancer growth and prevent its spread. One of the drugs has shown promise in treating other types of cancer as well.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
461 Participants Needed
Eflornithine + Sulindac for Colorectal Cancer Prevention
Baltimore, MarylandThe investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
354 Participants Needed
Fruquintinib for Colorectal Cancer
Baltimore, MarylandHigh blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib for refractory mCRC. Other aims are to learn how safe fruquintinib is and how well it is tolerated by participants.
Participants will receive fruquintinib in 4-week treatment cycles until their condition worsens, they do no longer tolerate the treatment or stop the treatment for other reasons. After the last treatment, participants will be checked upon every 3 months until study completion.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Uncontrolled Hypertension, Cardiovascular Disease, Others
Must Not Be Taking:Anticoagulants, TKIs, CYP3A4 Inducers
78 Participants Needed
Cemiplimab + Fianlimab for Colorectal Cancer
Baltimore, MarylandThe purpose of this study is to evaluate the safety and clinical activity of cemiplimab and the combination of cemiplimab/fianlimab in microsatellite unstable localized or locally advanced colorectal cancer diagnosed in patients age 70 or greater.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:70+
Sex:All
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Heart Disease, Metastatic Cancer, Others
Must Not Be Taking:Chronic Steroids
22 Participants Needed
Amivantamab + Chemotherapy for Colorectal Cancer
Baltimore, MarylandThis trial is testing a new medicine called amivantamab on patients with advanced colorectal cancer. The medicine helps the immune system find and destroy cancer cells. Researchers want to see how well it works alone and with standard chemotherapy.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:KRAS, NRAS, BRAF, EGFR, Others
225 Participants Needed
ERAS-007 Combination Therapy for Gastrointestinal Cancer
Baltimore, MarylandThis trial is testing a new drug called ERAS-007 combined with other cancer treatments to see if it is safe and effective for patients with advanced gastrointestinal cancers. The study focuses on patients with specific genetic mutations in their cancer cells, which are often hard to treat. ERAS-007 aims to target these mutations to help stop the cancer from growing.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 99
Sex:All
102 Participants Needed
Novel Interventions for Colorectal Cancer
Baltimore, MarylandThe main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
120 Participants Needed
KRAS Vaccine Combo for Colorectal and Pancreatic Cancer
Baltimore, MarylandPhase 1b study evaluating the efficacy and immune response to a synthetic long peptide mutant KRAS vaccine (SPL mKRASvax) combined with Balstilimab and Botensilimab for unresectable or metastatic mismatch repair-proficient (MMR-p) colorectal cancer (mCRC) or unresectable or metastatic MMR-p pancreatic ductal adenocarcinoma (PDAC) patients with measurable disease following first-line chemotherapy.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Autoimmune Disease, HIV, Others
Must Not Be Taking:Immunotherapy, Corticosteroids
54 Participants Needed
Cancer Vaccine + Nivolumab + Ipilimumab for Pancreatic and Colorectal Cancer
Baltimore, MarylandThis trial tests a special vaccine combined with immune-boosting drugs for patients with advanced pancreatic or colorectal cancer who have had extensive prior treatments. The goal is to train and enhance the immune system to better fight cancer. The vaccine has been used in previous studies to help the immune system recognize cancer cells in pancreatic cancer patients.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Brain Metastases, HIV, Others
Must Not Be Taking:Steroids, Chemotherapy, Immunotherapy, Others
30 Participants Needed
XL092 + Immuno-Oncology Agents for Solid Tumors
Baltimore, MarylandThis trial is testing a new drug called XL092 alone and with other cancer drugs in patients with advanced solid tumors. The goal is to see if these treatments can safely stop or slow tumor growth and help the immune system fight cancer more effectively.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Uncontrolled Illness, Pregnancy, Others
Must Not Be Taking:Anticoagulants, Complementary Medicines
1274 Participants Needed
AZD9592 for Solid Tumors
Baltimore, MarylandThis trial is testing a new drug called AZD9592 in patients with advanced solid tumors. The goal is to see if AZD9592 can help treat these cancers, either on its own or with other treatments. Researchers are looking at how safe the drug is, how well patients tolerate it, and if it can shrink or stop the growth of tumors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:ILD/pneumonitis, Spinal Cord Compression, Active Infection, Brain Metastases, Cardiac Comorbidities, Others
Must Not Be Taking:Corticosteroids
228 Participants Needed
Patient Navigation for Colorectal Cancer Screening
Baltimore, MarylandPatient navigation is an evidence-based strategy to increase screening rates among racial and ethnic minorities, but there is a gap in understanding the multi-level influences on implementation of such programs across primary care practices. The investigators will conduct a stepped-wedge, randomized trial to roll out patient navigation and patient and provider reminders across 15 clinics (3 clinics per step, 5 six-month steps). Implementation strategies will include assessing for readiness, audit and feedback, building a community coalition, engaging consumers, modifying referral tracking, and training and educating clinical stakeholders. The research team will use the electronic health record data with consideration for the Observational Medical Outcomes Partnership (OMOP) Common Data Model, additional patient-reported data, and study tracking logs to measure reach, effectiveness, adoption, implementation, and will use qualitative measures and site observations to document contextual factors, including examination of discrimination in patient experiences and provider referral patterns that may influence intervention delivery or colorectal cancer screening completion.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:45 - 75
Sex:All
1800 Participants Needed
Real-Time Feedback AI for Colonoscopy Quality Improvement
Baltimore, MarylandThis trial tests if giving doctors timely feedback during endoscopic exams can improve the quality of these procedures for patients.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
4150 Participants Needed
Colonoscopy vs FIT Screening for Colorectal Cancer
Baltimore, MarylandThis trial compares two methods for colorectal cancer screening in people aged 50-75. One method uses a camera to find and remove precancerous growths, while the other checks for hidden blood in stool. The study aims to see which method better reduces cancer deaths over time.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:50 - 75
Sex:All
50126 Participants Needed
CUE-102 for Cancer
Baltimore, MarylandThis trial is testing a new medicine called CUE-102 that helps the immune system fight cancer more effectively. It targets patients whose cancer hasn't responded to other treatments. The medicine works by activating immune cells to attack cancer cells more precisely.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Age:18+
Sex:All
52 Participants Needed
Nivolumab + Relatlimab for Colorectal Cancer
Baltimore, MarylandThis trial is testing two drugs, nivolumab and relatlimab, in patients with advanced colorectal cancer that is hard to treat. The drugs work by helping the immune system better recognize and attack cancer cells. The goal is to see if this combination is safe and effective for these patients.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Age:18+
Sex:All
59 Participants Needed
Ablative Therapy + Systemic Therapy for Colorectal Cancer
Baltimore, MarylandThis phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for patients who are not participating in a study is treatment with intravenous (IV) (through a vein) and/or oral medications (systemic therapy) to help stop the cancer sites from getting larger and the spread of the cancer to additional body sites. Ablative means that the intention of the local treatment is to eliminate the cancer at that metastatic site. The ablative local therapy will consist of very focused, intensive radiotherapy called stereotactic ablative radiotherapy (SABR) with or without surgical resection and/or microwave ablation, which is a procedure where a needle is temporarily inserted in the tumor and heat is used to destroy the cancer cells. SABR, surgical resection, and microwave ablation have been tested for safety, but it is not scientifically proven that the addition of these treatments are beneficial for your stage of cancer. The addition of ablative local therapy to all known metastatic sites to the usual approach of systemic therapy could shrink or remove the tumor(s) or prevent the tumor(s) from returning.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Liver-only Metastases, Unresectable Primary Tumors, Others
364 Participants Needed
Chemotherapy +/− Bevacizumab for Stage II Colon Cancer
Baltimore, MarylandThis randomized phase III trial studies oxaliplatin, leucovorin calcium, fluorouracil, and bevacizumab to see how well they work compared to oxaliplatin, leucovorin calcium, and fluorouracil in treating patients who have undergone surgery for stage II colon cancer. Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving combination chemotherapy together with bevacizumab is more effective than combination chemotherapy alone in treating colon cancer.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
2432 Participants Needed
NC410 + Pembrolizumab for Advanced Cancer
Baltimore, MarylandThis is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
97 Participants Needed
RMC-9805 for Solid Cancers
Baltimore, MarylandThis trial is testing a new oral drug, RMC-9805, in adults with a specific type of cancer mutation (KRAS G12D). The drug aims to block a faulty gene to potentially stop cancer growth.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:CNS Tumors, Brain Metastases, Others
Must Not Be Taking:KRAS Inhibitors
444 Participants Needed
LY3962673 for Pancreatic Cancer
Baltimore, MarylandThe main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Active CNS Metastases, Cardiovascular Disease, Infections, Others
540 Participants Needed
Chemotherapy + Atezolizumab for Colon Cancer
Baltimore, MarylandThis trial is testing whether adding atezolizumab to standard chemotherapy works better than chemotherapy alone for patients with stage III colon cancer who have a specific genetic defect. The chemotherapy drugs aim to kill cancer cells, while atezolizumab helps the immune system attack the cancer. Researchers hope this combination will improve survival rates and quality of life for these patients.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Age:12+
Sex:All
700 Participants Needed
MRTX1133 for Solid Cancers
Baltimore, MarylandA Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
386 Participants Needed
Pancreatic Cancer Screening for Pancreatic Cancer
Baltimore, MarylandThis trial is overseen by Johns Hopkins clinical research office. Team members at each location will report any major issues to the lead researcher.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Coagulopathy, Prior Surgery, Pregnancy, Others
9000 Participants Needed
Tisotumab Vedotin for Cancer
Baltimore, MarylandThis trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study.
* In Part A, the treatment will be given to participants every 3 weeks (3-week cycles).
* In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle.
* In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle.
* In Part D, participants will be given treatment on Day 1 of every 3-week cycle. Participants in Part D will get tisotumab vedotin with either:
* Pembrolizumab or,
* Pembrolizumab and carboplatin, or
* Pembrolizumab and cisplatin
* In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle.
* In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part F will get tisotumab vedotin with pembrolizumab.
* In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part G will get tisotumab vedotin with pembrolizumab and carboplatin.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
352 Participants Needed
MRTX0902 + MRTX849 for Solid Tumors
Baltimore, MarylandThis trial is testing a new drug, MRTX0902, alone and with another drug, adagrasib, in patients with advanced cancers that have specific genetic mutations. The goal is to see if these drugs are safe and can effectively block cancer growth signals. Adagrasib has shown promising results in treating certain types of advanced cancers.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Hemoptysis, Pneumonitis, Others
Must Not Be Taking:CYP3A Substrates, P-gp Inhibitors
228 Participants Needed
Page 1 of 4+
Learn More About Power
My name is Bask, and I helped to start the company here. We started Power when my Dad was diagnosed with multiple myeloma, and I needed a better way to understand how he could access the most promising immunotherapy for his illness.
Bask GillCEO at Power
Frequently Asked Questions
How much do Colorectal Cancer clinical trials in Baltimore, MD pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Colorectal Cancer clinical trials in Baltimore, MD work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Colorectal Cancer trials in Baltimore, MD 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Baltimore, MD for Colorectal Cancer is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Baltimore, MD several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Colorectal Cancer medical study in Baltimore, MD ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Colorectal Cancer clinical trials in Baltimore, MD ?
Most recently, we added CAR T Cells for Mesothelioma, Immunotherapy + Radiation for Colorectal Cancer and Ipilimumab + Nivolumab for Colorectal Cancer to the Power online platform.